Chemistry:Lucid-PSYCH

From HandWiki

Lucid-PSYCH, or LUCID-PSYCH, also known as Lucid-201, is a psychedelic hallucinogen which is under development for the treatment of major depressive disorder.[1][2][3][4][5] It is under development by Lucid Psycheceuticals.[1][2] Lucid-PSYCH's exact mechanism of action is undefined.[1][2] As of March 2023, it is in preclinical research and is progressing to phase 1 clinical trials.[1][2][6]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 "Lucid PSYCH - AdisInsight". https://adisinsight.springer.com/drugs/800065212. 
  2. ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on Lucid-201 with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/315ebebe9dff40e39dc4f77194749eac. 
  3. ↑ "Mental health disorders | Neurodegenerative disorders | Toronto". https://www.lucidpsycheceuticals.com/pipeline. 
  4. ↑ "Our Science". https://fsdpharma.com/our-science/. 
  5. ↑ https://www.sec.gov/Archives/edgar/data/1771885/000115752321001089/a52478064_ex991.htm "Lucid’s pipeline includes Lucid-201, a psychedelic drug candidate targeting mental health disorders, [...]"
  6. ↑ "Registration". https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12623000423617. 


Template:Psychedelics




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Lucid-PSYCH&oldid=4036683"